Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina

OBJECTIVES: The impact of amiodarone on mortality in patients with severe congestive heart failure (CHF) (New York Heart Association functional classes II [advanced], III and IV; left ventricular ejection fraction < 35%) In the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial was analyzed in relation to initial mean baseline heart rate (BHR) and its change after 6 months of follow-up. BACKGROUND: Trials of amiodarone therapy in CHF have produced discordant results, suggesting that the effect is not uniform in all patient subgroups with regard to survival. METHODS: The present analysis was carried out in 516 patients randomized to receive amiodarone, 300 mg/day (n = 260), or nonantiarrhythmic therapy (n = 256, control group) and followed up for 2 years. Survival was evaluated for patients with a BHR > or = 90 beats/min (control: n = 132; amiodarone: n = 122) and < 90 beats/min (control: n = 124; amiodarone: n = 138). Survival was also analyzed according to heart rate reduction at 6 months for 367 patients. RESULTS: For patients with a BHR > or = 90 beats/min, amiodarone therapy reduced mortality to 38.4% compared with 62.4% in control patients (relative risk [RR] 0.55, 95% confidence interval [CI] 0.35 to 0.95, p < 0.002). Both sudden death (RR 0.46, 95% CI 0.24 to 0.90, p < 0.02) and progressive heart failure death (RR 0.60, 95% CI 0.30 to 1.03, p < 0.06) were reduced, and functional capacity was improved. In patients with a BHR < 90 beats/min, amiodarone did not alter survival. Among 367 patients who completed 6 months of follow-up, amiodarone reduced 2-year mortality only in those with a BHR > or = 90 beats/min, which was reduced at 6 months. CONCLUSIONS: Elevated rest heart rates in severe CHF identify a subgroup of patients who benefit from treatment with amiodarone. Amiodarone-induced heart rate slowing may be an important benefit for patients.

This article has been cited by other articles:

				R. Kolloch, U. F. Legler, A. Champion, R. M. Cooper-DeHoff, E. Handberg, Q. Zhou, and C. J. Pepine Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST) Eur. Heart J., May 2, 2008; 29(10): 1327 - 1334. [Abstract] [Full Text] [PDF]

				A S Hall and S Palmer The heart rate hypothesis: ready to be tested Heart, May 1, 2008; 94(5): 561 - 565. [Abstract] [Full Text] [PDF]

				C. Melzer, J. Witte, R. Reibis, H.J. Bondke, W. Combs, K. Stangl, G. Baumann, and H. Theres Predictors of chronotropic incompetence in the pacemaker patient population. Europace, January 1, 2006; 8(1): 70 - 75. [Abstract] [Full Text] [PDF]

				M. Metra, C. Torp-Pedersen, K. Swedberg, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, B. Lutiger, A. Scherhag, M. A. Lukas, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial Eur. Heart J., November 1, 2005; 26(21): 2259 - 2268. [Abstract] [Full Text] [PDF]

				B. N. Singh More on Amiodarone-Meeting the Challenges of the Combined Epidemics of Heart Failure and Atrial Fibrillation? Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 175 - 178. [PDF]

				D. C. Choo, B. Huiskes, J. Jones, S. Fabbri, L. A. Hawkins, K. Chatterjee, T. De Marco, and J. T. Heywood Amiodarone Rescue Therapy for Severe Decompensated Heart Failure Initially Unsuitable for {beta}-Blockers Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 187 - 192. [Abstract] [PDF]

				L. Tavazzi Heart rate as a therapeutic target in heart failure? Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G15 - G18. [Abstract] [PDF]

				J.P. Vilaine, C. Thollon, N. Villenueve, and J.L. Peglion Procoralan, a new selective If current inhibitor Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G26 - G35. [Abstract] [PDF]

				A. Malhotra, V. V. Muse, and E. J. Mark Case 12-2003 - An 82-Year-Old Man with Dyspnea and Pulmonary Abnormalities N. Engl. J. Med., April 17, 2003; 348(16): 1574 - 1585. [Full Text] [PDF]

				R H Arnold, E Kotlyar, C Hayward, A M Keogh, and P S Macdonald Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study Heart, March 1, 2003; 89(3): 293 - 298. [Abstract] [Full Text] [PDF]

				D. J. van Veldhuisen and W. H. van Gilst The pharmacological management of heart failure: too many treatments? Eur J Heart Fail, January 1, 2003; 5(1): 5 - 8. [Full Text] [PDF]

				R.A de Boer and D.J van Veldhuisen Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D111 - D116. [Abstract] [PDF]

				H. Yonemochi, S. Yasunaga, Y. Teshima, N. Takahashi, M. Nakagawa, M. Ito, and T. Saikawa Rapid Electrical Stimulation of Contraction Reduces the Density of {beta}-Adrenergic Receptors and Responsiveness of Cultured Neonatal Rat Cardiomyocytes : Possible Involvement of Microtubule Disassembly Secondary to Mechanical Stress Circulation, June 6, 2000; 101(22): 2625 - 2630. [Abstract] [Full Text] [PDF]

				M. Malik, A. J. Camm, M. J. Janse, D. G. Julian, G. A. Frangin, P. J. Schwartz, and on behalf of the EMIAT Investigators Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial) J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1263 - 1275. [Abstract] [Full Text] [PDF]

				D. M. Kaye, A. M. Dart, G. L. Jennings, and M. D. Esler Antiadrenergic effect of chronic amiodarone therapy in human heart failure J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1553 - 1559. [Abstract] [Full Text] [PDF]

				T Laperche, D Logeart, A Cohen-Solal, and R Gourgon Potential interests of heart rate lowering drugs Heart, April 1, 1999; 81(4): 336 - 341. [Full Text]

				P. Palatini, E. Casiglia, S. Julius, and A. C. Pessina High Heart Rate: A Risk Factor for Cardiovascular Death in Elderly Men Arch Intern Med, March 22, 1999; 159(6): 585 - 592. [Abstract] [Full Text] [PDF]

				P. Palatini Need for a Revision of the Normal Limits of Resting Heart Rate Hypertension, February 1, 1999; 33(2): 622 - 625. [Full Text] [PDF]

				M. Zabel, T. Klingenheben, M. R. Franz, and S. H. Hohnloser Assessment of QT Dispersion for Prediction of Mortality or Arrhythmic Events After Myocardial Infarction : Results of a Prospective, Long-term Follow-up Study Circulation, June 30, 1998; 97(25): 2543 - 2550. [Abstract] [Full Text] [PDF]

				R. P Steeds and K. S Channer Drug treatment in heart failure BMJ, February 14, 1998; 316(7131): 567 - 568. [Full Text]

				Who Benefits From Amiodarone? Journal Watch Cardiology, May 19, 1997; 1997(519): 3 - 3. [Full Text]